Blockage of immune-mediated inner ear damage by etanercept

Otology and Neurotology

Volumn 24, Issue 1, 2003, Pages 52-57

  Wang, Xiaobo ^a   Truong, Tim ^a   Billings, Peter B ^a   Harris, Jeffrey P ^a   Keithley, Elizabeth M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cochlea; Immune response; Inflammation; Inner ear; Tumor necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; ETANERCEPT; KEYHOLE LIMPET HEMOCYANIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COCHLEA; CONTROLLED STUDY; EAR INJURY; EVOKED AUDITORY RESPONSE; GUINEA PIG; HEARING LOSS; IMMUNE RESPONSE; INFLAMMATION; INNER EAR; LABYRINTHITIS; NONHUMAN; OTOTOXICITY; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AUDITORY THRESHOLD; AUTOIMMUNE DISEASES; FEMALE; GUINEA PIGS; HEARING LOSS, SENSORINEURAL; HEMOCYANIN; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INFUSION PUMPS; LABYRINTHITIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037260742     PISSN: 15317129     EISSN: None     Source Type: Journal    
DOI: 10.1097/00129492-200301000-00012     Document Type: Article

References (21)

1. McCabe BF. Autoimmune inner ear disease: therapy. Am J Otol 1989;10:196-7.
2. Sismanis A, Wise CM, Johnson GD. Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg 1997;116:146-52.
3. Salley LH, Grimm M, Sismanis A, et al. Methotrexate in the management of immune mediated cochleovestibular disorders: clinical experience with 53 patients. J Rheumatol 2001;28:1037-40.
4. Matteson EL, Tirzaman O, Facer GW, et al. Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 2000;109:710-4.
5. Matteson EL, Fabry DA, Facer GW, et al. Open trial of methotrexate as treatment of autoimmune hearing loss. Arthritis Rheum 2001;45:146-50.
6. Harris JP. Immunology of the inner ear: response of the inner ear to antigen challenge. Otolaryngol Head Neck Surg 1983;91:18-32.
7. Harris JP, Fukuda S, Keithley EM. Spiral modiolar vein: its importance in inner ear inflammation. Acta Otolaryngol 1990;110:357-65.
8. Ma C-L, Billings P, Harris JP, et al. Characterization of an experimentally induced inner ear immune response. Laryngoscope 2000;110:451-6.
9. Darmstadt GL, Keithley EM, Harris JP. Effects of cyclophosphamide on the pathogenesis of cytomegalovirus-induced labyrinthitis. Ann Otol Rhinol Laryngol 1990;99:960-8.
10. Takasu T, Harris JP. Reduction of inner ear inflammation by treatment with anti-ICAM-1 antibody. Ann Otol Rhinol Laryngol 1997;106:1070-5.
11. Yang GSY, Song H-T, Keithley EM, et al. Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss. Am J Otol 2000;21:499-504.
12. Satoh H, Firestein, GS, Billings PB, et al. TNFα, an initiator and etanercept, an inhibitor of inner ear inflammation. Laryngoscope 2002;112:1627-34.
13. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993;151:1548-61.
14. Wooley PH, Dutcher J, Widmer MB, et al. Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993;151:6602-7.
15. Brennan FM, Chantry D, Jackson A, et al. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
16. Rahman MU, Poe DS, Choi HK. Etanercept therapy for immunemediated cochleovestibular disorders: preliminary results in a pilot study. Otol Neurotol 2001;22:619-24.
17. Prieskorn DM, Miller JM. Technical report: chronic and acute intracochlear infusion in rodents. Hear Res 2000;140:212-5.
18. Springer TA, Dustin ML, Kishimoto TK, et al. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Ann Rev Immunol 1987;5:223-52.
19. Dustin ML, Staunton DE, Springer TA. Supergene families meet in the immune system. Immunol Today 1988;9:213-5.
20. Keithley EM, Harris JP. Late sequelae of cochlear infection. Laryngoscope 1996;106:341-5.
21. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.